Liver Cancer

Primary liver cancer — the most common form of which is known as hepatocellular carcinoma — has one of the fastest-rising cancer incidence of any malignant tumor in the U.S. It is the third leading cause of cancer-related death worldwide.

The Mount Sinai Medical Center has been at the forefront of the clinical management of liver cancer in the United States. The Mount Sinai Hospital is the leading center in the U.S. in terms of the number of new liver cancer patients evaluated annually.

Mount Sinai is also a leader in researching new treatments for liver cancer. As a result, our patients often have access to new treatments before they are available elsewhere. Mount Sinai was the largest patient recruitment site in the country for studies of sorafenib, the first treatment proven to extend life for patients with advanced liver cancer.